Globally, 296 million people are infected with hepatitis B virus (HBV), and approximately one
million people die annually from HBV-related causes, including liver cancer. Although there …

Hepatitis B virus (HBV) is a hepatotropic virus that can establish a persistent and chronic
infection in humans through immune anergy. Currently, 3.5% of the global population is …

Conclusions Despite clear relationships between HBV RNA and HBcrAg levels and CHB
phases, these markers have limited additional value in differentiating CHB phases because …

Background & Aims It has been proposed that serum hepatitis B core-related antigen
(HBcrAg) reflects intrahepatic covalently closed circular (ccc) DNA levels. However, the …

Background and Aims NAFLD is the most common liver disease worldwide. NASH, the
progressive form of NAFLD, and advanced fibrosis are associated with poor outcomes. We …

Hepatitis B virus (HBV) cannot be eliminated completely from infected hepatocytes because
of the presence of intrahepatic covalently closed circular DNA (cccDNA). As chronic hepatitis …

Background and Aims The clinical utility of two biomarkers, hepatitis B virus (HBV) RNA and
hepatitis B core‐related antigen (HBcrAg), as compared to conventional markers of HBV …

Even though an approved vaccine for hepatitis B virus (HBV) is available and widely used,
over 257 million individuals worldwide are living with chronic hepatitis B (CHB) who require …

With its 78 million chronic carriers, hepatitis B virus (HBV) infection is still one of the leading
public health challenges in China. Over the last two decades, China has made great …

Viral biomarkers are important tools for monitoring chronic hepatitis B virus (HBV) hepatitis B
early antigen (HBeAg) negative infection, both in its natural course as well as during and …